Prognostic Factors in Unknown Primary Cancer

被引:26
作者
Culine, Stephane [1 ]
机构
[1] CHU Henri Mondor, Dept Med Oncol, F-94010 Creteil, France
关键词
POORLY DIFFERENTIATED CARCINOMA; PRIMARY SITE; CONSECUTIVE PATIENTS; SURVIVAL; ADENOCARCINOMA; COMBINATION; CISPLATIN; PREDICT; MODEL;
D O I
10.1053/j.seminoncol.2008.10.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In patients with unknown primary cancer, the diagnostic uncertainty as to the nature of the primary cancer also affects the formulation of a prognosis. Only in a minority of patients, the similarity of the clinical presentations to those of known primary cancers at a similar stage has resulted in the identification of subsets of patients with favorable clinical and pathological features. Their recognition is of major importance since specific treatment guidelines may translate into prolonged survival. For the vast majority of patients with unknown primary cancer and unfavorable outcome features, the identification of reliable prognostic indicators has proven challenging. A number of studies with multivariate analyses identified poor performance status, liver metastases, and abnormal serum lactic dehydrogenase (LDH) levels as the main recurrent adverse prognostic factors. No international consensus has been defined. The knowledge of prognostic factors may help the oncologist to refine the daily management of patients, to assess the results of clinical trials, and to design more useful clinical research studies. © 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:60 / 64
页数:5
相关论文
共 12 条
[1]   UNKNOWN PRIMARY-CARCINOMA - NATURAL-HISTORY AND PROGNOSTIC FACTORS IN 657 CONSECUTIVE PATIENTS [J].
ABBRUZZESE, JL ;
ABBRUZZESE, MC ;
HESS, KR ;
RABER, MN ;
LENZI, R ;
FROST, P .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1272-1280
[2]   Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group study [J].
Briasoulis, E ;
Kalofonos, H ;
Bafaloukos, D ;
Samantas, E ;
Fountzilas, G ;
Xiros, N ;
Skarlos, D ;
Christodoulou, C ;
Kosmidis, F ;
Pavlidis, N .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3101-3107
[3]   Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site:: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) [J].
Culine, S ;
Lortholary, A ;
Voigt, JJ ;
Bugat, R ;
Théodore, C ;
Priou, F ;
Kaminsky, MC ;
Lesimple, T ;
Pivot, X ;
Coudert, B ;
Douillar, JY ;
Merrouche, Y ;
Allouache, J ;
Goupil, A ;
Négrier, S ;
Viala, J ;
Petrow, P ;
Bouzy, J ;
Laplanche, A ;
Fizazi, K .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3479-3482
[4]   Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site [J].
Culine, S ;
Kramar, A ;
Saghatchian, M ;
Bugat, R ;
Lesimple, T ;
Lortholary, A ;
Merrouche, Y ;
Laplanche, A ;
Fizazi, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4679-4683
[5]   ADVANCED POORLY DIFFERENTIATED CARCINOMA OF UNKNOWN PRIMARY SITE - RECOGNITION OF A TREATABLE SYNDROME [J].
GRECO, FA ;
VAUGHN, WK ;
HAINSWORTH, JD .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (04) :547-553
[6]   POORLY DIFFERENTIATED CARCINOMA OF UNKNOWN PRIMARY SITE - CLINICAL USEFULNESS OF IMMUNOPEROXIDASE STAINING [J].
HAINSWORTH, JD ;
WRIGHT, EP ;
JOHNSON, DH ;
DAVIS, BW ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (11) :1931-1938
[7]   CISPLATIN-BASED COMBINATION CHEMOTHERAPY IN THE TREATMENT OF POORLY DIFFERENTIATED CARCINOMA AND POORLY DIFFERENTIATED ADENOCARCINOMA OF UNKNOWN PRIMARY SITE - RESULTS OF A 12-YEAR EXPERIENCE [J].
HAINSWORTH, JD ;
JOHNSON, DH ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :912-922
[8]  
Hess KR, 1999, CLIN CANCER RES, V5, P3403
[9]   Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? [J].
Lenzi, R ;
Hess, KR ;
Abbruzzese, MC ;
Raber, MN ;
Ordonez, NG ;
Abbruzzese, JL .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2056-2066
[10]  
Lortholary A, 2001, B CANCER, V88, P619